8-K: Odyssey Health Secures $25M Equity Funding

Odyssey Health, Inc. entered into a $25 million equity purchase agreement with Mast Hill Fund L.P. to bolster its financial position and fund operations.

Summary

• Odyssey Health, Inc. (ODYY) entered into a Purchase Agreement with Mast Hill Fund L.P. on July 29, 2025, allowing Mast Hill to purchase up to $25,000,000 of Odyssey common stock over a 24-month term.
• The Company retains sole discretion over the timing and amount of common stock sales to Mast Hill, up to 20,000,000 shares.
• The purchase price for shares sold to Mast Hill will be based on a fixed discount to the market price, specifically the lesser of 97% of the Market Price or 102% of the Market Alternative Price during the valuation period.
• A Registration Rights Agreement was also executed, requiring Odyssey to file a registration statement with the SEC within 45 calendar days to register the shares for resale by Mast Hill, aiming for effectiveness within 90 calendar days.
• Proceeds from the agreement are intended for general corporate purposes, working capital, capital expenditures, research and development, and operational expenses, including officer compensation.
• Mast Hill's beneficial ownership is limited to 4.99% of the Company's total outstanding common stock at any single point in time.
• The Company is prohibited from entering into certain 'Variable Rate Transactions' for 24 months, excluding At-the-Market offerings with registered broker-dealers.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. Securing a $25 million equity line provides crucial capital access and financial flexibility for Odyssey Health, which is a significant positive for its operations and growth. However, the potential for shareholder dilution due to sales at a discount to market price and the prohibition on certain future financing types introduce a degree of caution.

Positives

• Secures access to up to $25,000,000 in capital, providing significant funding for general corporate purposes, working capital, capital expenditures, research and development, and operational expenses.
• The Company maintains control over the timing and amount of common stock sales, allowing for strategic management of capital inflows.
• The agreement has a 24-month term, providing a sustained period for capital access.
• The Company can terminate the Purchase Agreement at any time without fee, penalty, or cost upon one business day notice, offering flexibility.
• No restrictions on future financings or rights of first refusal, allowing the Company to raise capital from other sources at its discretion (with the exception of Variable Rate Transactions).

Negatives

• Sales of common stock to Mast Hill will occur at a fixed discount to the market price, leading to dilution for existing shareholders.
• The prohibition on 'Variable Rate Transactions' for 24 months could limit certain future financing options, although At-the-Market offerings are excluded.
• The agreement requires the Company to pay $17,500.00 to Mast Hill for reimbursement of legal expenses related to the preparation of the agreement.

Risks

• Share price volatility could impact the effective capital raised, as the purchase price is tied to a discount to market price.
• Potential for significant shareholder dilution as shares are sold to Mast Hill over time.
• Failure to maintain SEC registration statement effectiveness or timely delivery of shares could trigger 'Buy-In' provisions, requiring the Company to compensate Mast Hill for losses.
• The 4.99% beneficial ownership limitation for Mast Hill may require multiple tranches of share issuances and registrations, adding administrative complexity.
• Risk of trading suspension or delisting of common stock, which would allow Mast Hill to return Put Shares and reduce the purchase price.

Future Outlook

The Company anticipates using the newly secured capital for general corporate purposes, working capital, capital expenditures, research and development, and operational expenses over the next 24 months. The effectiveness of the registration statement is a key near-term milestone to enable the draw-down of funds.

Industry Context

This equity line of credit is a common financing mechanism for smaller, publicly traded companies, particularly those on OTC markets, seeking flexible access to capital without the immediate upfront costs or stringent covenants of traditional debt or underwritten equity offerings. It allows companies to draw funds as needed, aligning with operational requirements and market conditions, while potentially minimizing immediate dilution compared to a large single offering.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards. Equity lines of credit are a standard financing tool, and the terms (e.g., 24-month term, discount to market, beneficial ownership limits) are generally within typical ranges for such agreements for companies of this size and market capitalization.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution due to the issuance of new shares at a discount to market price. However, the capital infusion can support company growth and stability, potentially benefiting long-term shareholder value.
• Employees: Proceeds allocated for operational expenses and officer compensation could ensure continued employment and potentially support growth initiatives.
• Creditors: Improved liquidity and financial stability from the capital raise could enhance the Company's ability to meet its obligations.
• Customers/Suppliers: Enhanced financial health may lead to more stable operations and better ability to fulfill commitments.

Next Steps

• The Company must file a registration statement with the SEC within 45 calendar days of July 29, 2025, to register the shares for resale by Mast Hill.
• The Company must ensure the registration statement is declared effective by the SEC within 90 calendar days of July 29, 2025.
• The Company will begin directing Mast Hill to purchase common stock once all conditions, including SEC effectiveness, are satisfied.
• The Company will use the proceeds for general corporate purposes, working capital, capital expenditures, research and development, and operational expenses.

Key Dates

Recommendation

The equity line of credit provides Odyssey Health with much-needed capital flexibility, which is a positive for its operational stability and future growth initiatives. However, the inherent dilution from selling shares at a discount to market price, coupled with the 4.99% beneficial ownership limit for the investor, suggests a gradual and potentially prolonged dilution effect. While the capital is beneficial, the terms do not present an overwhelmingly strong catalyst for immediate significant upside, nor do they indicate severe distress. A 'hold' recommendation is appropriate as investors should monitor the Company's utilization of funds and the impact of dilution on per-share metrics.

Keywords

Equity Purchase Agreement, Capital Raise, SEC Filing, ODYY, Mast Hill Fund, Common Stock, Dilution, Financing, Registration Rights, OTC Markets